Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging

B. Vorlová, F. Sedlák, P. Kašpárek, K. Šrámková, M. Malý, J. Zámečník, P. Šácha, J. Konvalinka,

. 2019 ; 79 (2) : 126-139. [pub] 20180905

Language English Country United States

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc19045221

BACKGROUND: Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is an important diagnostic and therapeutic target in prostate cancer. PSMA/GCPII is also expressed in many healthy tissues, but its function has only been established in the brain and small intestine. Several research groups have attempted to produce PSMA/GCPII-deficient mice to study the physiological role of PSMA/GCPII in detail. The outcomes of these studies differ dramatically, ranging from embryonic lethality to production of viable PSMA/GCPII-deficient mice without any obvious phenotype. METHODS: We produced PSMA/GCPII-deficient mice (hereafter also referred as Folh1-/- mice) by TALEN-mediated mutagenesis on a C57BL/6NCrl background. Using Western blot and an enzyme activity assay, we confirmed the absence of PSMA/GCPII in our Folh1-/- mice. We performed anatomical and histopathological examination of selected tissues with a focus on urogenital system. We also examined the PSMA/GCPII expression profile within the mouse urogenital system using an enzyme activity assay and confirmed the presence of PSMA/GCPII in selected tissues by immunohistochemistry. RESULTS: Our Folh1-/- mice are viable, breed normally, and do not show any obvious phenotype. Nevertheless, aged Folh1-/- mice of 69-72 weeks exhibit seminal vesicle dilation, which is caused by accumulation of luminal fluid. This phenotype was also observed in Folh1+/- mice; the overall difference between our three cohorts (Folh1-/- , Folh1+/- , and Folh1+/+ ) was highly significant (P < 0.002). Of all studied tissues of the mouse urogenital system, only the epididymis appeared to have a physiologically relevant level of PSMA/GCPII expression. Additional experiments demonstrated that PSMA/GCPII is also present in the human epididymis. CONCLUSIONS: In this study, we provide the first evidence characterizing the reproductive tissue phenotype of PSMA/GCPII-deficient mice. These findings will help lay the groundwork for future studies to reveal PSMA/GCPII function in human reproduction.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19045221
003      
CZ-PrNML
005      
20200318103332.0
007      
ta
008      
200109s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/pros.23717 $2 doi
035    __
$a (PubMed)30256431
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vorlová, Barbora $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. First Faculty of Medicine, Charles University, Prague 2, Czech Republic.
245    12
$a A novel PSMA/GCPII-deficient mouse model shows enlarged seminal vesicles upon aging / $c B. Vorlová, F. Sedlák, P. Kašpárek, K. Šrámková, M. Malý, J. Zámečník, P. Šácha, J. Konvalinka,
520    9_
$a BACKGROUND: Prostate-specific membrane antigen (PSMA), also known as glutamate carboxypeptidase II (GCPII), is an important diagnostic and therapeutic target in prostate cancer. PSMA/GCPII is also expressed in many healthy tissues, but its function has only been established in the brain and small intestine. Several research groups have attempted to produce PSMA/GCPII-deficient mice to study the physiological role of PSMA/GCPII in detail. The outcomes of these studies differ dramatically, ranging from embryonic lethality to production of viable PSMA/GCPII-deficient mice without any obvious phenotype. METHODS: We produced PSMA/GCPII-deficient mice (hereafter also referred as Folh1-/- mice) by TALEN-mediated mutagenesis on a C57BL/6NCrl background. Using Western blot and an enzyme activity assay, we confirmed the absence of PSMA/GCPII in our Folh1-/- mice. We performed anatomical and histopathological examination of selected tissues with a focus on urogenital system. We also examined the PSMA/GCPII expression profile within the mouse urogenital system using an enzyme activity assay and confirmed the presence of PSMA/GCPII in selected tissues by immunohistochemistry. RESULTS: Our Folh1-/- mice are viable, breed normally, and do not show any obvious phenotype. Nevertheless, aged Folh1-/- mice of 69-72 weeks exhibit seminal vesicle dilation, which is caused by accumulation of luminal fluid. This phenotype was also observed in Folh1+/- mice; the overall difference between our three cohorts (Folh1-/- , Folh1+/- , and Folh1+/+ ) was highly significant (P < 0.002). Of all studied tissues of the mouse urogenital system, only the epididymis appeared to have a physiologically relevant level of PSMA/GCPII expression. Additional experiments demonstrated that PSMA/GCPII is also present in the human epididymis. CONCLUSIONS: In this study, we provide the first evidence characterizing the reproductive tissue phenotype of PSMA/GCPII-deficient mice. These findings will help lay the groundwork for future studies to reveal PSMA/GCPII function in human reproduction.
650    _2
$a stárnutí $x metabolismus $x patologie $7 D000375
650    _2
$a zvířata $7 D000818
650    _2
$a antigeny povrchové $x genetika $x metabolismus $7 D000954
650    _2
$a glutamátkarboxypeptidasa II $x nedostatek $x genetika $x metabolismus $7 D043425
650    _2
$a lidé $7 D006801
650    _2
$a imunohistochemie $7 D007150
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a membránové glykoproteiny $x nedostatek $x genetika $x metabolismus $7 D008562
650    _2
$a myši $7 D051379
650    _2
$a myši inbrední C57BL $7 D008810
650    _2
$a semenné váčky $x enzymologie $x patologie $7 D012669
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Sedlák, František $7 xx0245929 $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. First Faculty of Medicine, Charles University, Prague 2, Czech Republic. Faculty of Science, Department of Genetics and Microbiology, Charles University, Prague 2, Czech Republic.
700    1_
$a Kašpárek, Petr $u Laboratory of Transgenic Models of Diseases, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic. Czech Centre for Phenogenomics, Institute of Molecular Genetics of the Czech Academy of Sciences, Vestec, Czech Republic.
700    1_
$a Šrámková, Karolína $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic.
700    1_
$a Malý, Marek $u National Institute of Public Health, Prague 10, Czech Republic.
700    1_
$a Zámečník, Josef $u Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague 5, Czech Republic.
700    1_
$a Šácha, Pavel $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic.
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague 6, Czech Republic. Department of Biochemistry, Faculty of Science, Charles University, Prague 2, Czech Republic.
773    0_
$w MED00010484 $t The Prostate $x 1097-0045 $g Roč. 79, č. 2 (2019), s. 126-139
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30256431 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200109 $b ABA008
991    __
$a 20200318103757 $b ABA008
999    __
$a ok $b bmc $g 1483490 $s 1083894
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 79 $c 2 $d 126-139 $e 20180905 $i 1097-0045 $m The Prostate $n Prostate $x MED00010484
LZP    __
$a Pubmed-20200109

Find record

Citation metrics

Archiving options